Some Recent Developments in the Pharmacology of Heparin by Coon, William W.
Some Recent Developments in the
Pharmacology of Heparin
WILLIAM W. COON. M.D. Ann Arbor, Mich.
July 1979 337
LTHOUOH investigations of the pharma-
cology of heparin extend back more
than 60 years, much remains to be
learned. In spite of the fact that this
agent has had a wide and expanding
clinical use, it has not been isolated in
chemically pure form, its structure is not
fully defined, and differences between its
anticoagulant and antithrombotic effect
have not yet been elucidated. The in.
creasing requirements for heparin for
both prophylactic and therapeutic pur-
poses require that current and new
knowledge be rapidly assimilated into
clinical practice. This commentary re-
views briefly and selectively some of the
recent developments which may be of
practical use in the care of patients or
serve as a focus for future research.
Chemistry
Commercial heparin or heparin which
has undergone further purification for re-
search purposes is not a single chemical
entity. When heparin is extracted from
natural sources, fractions with molecular
weights between 6000 and 30,000 have
been shown to have significant but vari-
able anticoagulant activity.’ Heparins
with molecular weights below 6000 have
a negligible anticoagulant effect.
The basic structural unit of heparin
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has now been reasonably well defined. It
contains three hexose derivatives in ring
form (hexopyranosides): D-glucosamlne,
n-glucuronic acid, and L-idurOnic acid.
The basic structural unit appears to be
a hexasaceharide containing two disac-
charides of 2-sulfoiduronic acid-2-sulfo-
glucosamine and one disaccharide of gin-
curonic acid-2-sulfoglucosamine in a 1,4-
alpha-glycosidic linkage.2 These units ap-
pear to be arranged in an unbranched
linear chain.3 Commercial heparins con-
tain at least 21 components with variable
chain lengths of 6000 to 30,000 daltons4
and with differing elemental composition,
electrophoretic mobility, and nuclear
magnetic spectrum.5 These separate com-
ponents have varying anticoagulant ac-
tivity when measured by U.S.P. assay.
An important element that has not yet
been clarified is the critical structural
characteristic required for anticoagulant
activity. Recent studies have shown that
it is not one but a combination of prop-
erties which are required: free carboxyl
groups, 0-sulfate ester groups on hexur-
onic acid, and giucosamine and the sul-
famino groups of glucosamine.#{176}8 Altera-
tion of shape of the molecule may also
influence anticoagulant effect.9
The utilization of affinity chromatogra-
phy has recently resulted in the clear
demonstration of the heterogeneity of
heparin on the basis of binding of hep-
arm preparations to antithrombin Ill
(heparin cofactor) .101 In one commer-
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cial product, one third of the isolated
material contained 85 per cent of the
anticoagulant activity.” “Active” and
‘‘inactive’’ fractions are similar in chemi-
cal composition, but the ‘‘active” ma-
terial had a higher net negative charge
density.’#{176} This promising approach may
result in the preparation of a product
with a more consistent anticoagulant ef-
feet.
Assay of Heparin
Methods of assay of heparin in vitro
may vary with the source of heparin,
source of blood used in the test, and test
method and may not coincide with anti-
coagulant or antithrombotic effect in vivo.
However, no procedure has yet been dem-
onstrated to be distinctly superior to the
U.S.P. assay. Since results of bioassay of
heparin from lung and intestinal mucosa
have shown differences when the British
and United States pharmacopoeial meth-
ods are compared, it has been suggested
that the assay of heparin derived from a
specific tissue be performed with a stand-
ard obtained from the same tissue and
animal species and that multiple rather
than single coagulation tests be used.’2
The heterogeneity of heparin and the
multiplicity of possible test procedures
complicate the process of standardiza-
tion. Heparin standards have not been
characterized by physical or chemical
methods. Reagents may vary from one
laboratory to another. Different test meth-
ods measure different spectra of clotting
factor activities. Although assay of hep-
arm in vivo has been proposed as an al-
ternative approach,’3 it is subject to the
same types of problems encountered in
testing in vitro.
In spite of the many problems in the
laboratory standardization of commercial
heparins, clinicians have encountered few
well-documented differences in apparent
antithrombotic effectiveness between dif-
ferent products. In recent years contro-
versial claims have been made concern-
ing the superiority of heparin derived
from lung as opposed to the product from
ititestinal mucosa. However, when con-
trolled comparative studies have been con-
ducted, no significant differences in anti-
coagulant effect have been found.’4’6 The
thrombocytopenia occasionally appearing
during heparin therapy has been ob-
served with both lung and mucosal hep-
aria.’7”8 However, because of the many
variables associated with the clinical as-
sessment of antithrombotic effectiveness,
the failure to observe differences does not
necessarily mean they do not exist. The
recent widespread use of low-dose heparin
for prophylactic purposes may make ac-
curate standardization more important
since variations in potency may have
greater significance under these condi-
tions.’9
Absorption, Distribution, and Metabolism
Administration of commercial heparin
in massive doses to man by oral, buccal,
or rectal routes has not resulted in signi-
ficant effects upon lipemia clearing or co-
agulation.20 Recently, a depolymerized
low molecular weight heparin (molecular
weight 4700-5300) has been shown to pro-
long clotting times after buccal applica-
tion in mice.2’ The demonstration of an
apparent anticoagulant effect by such
low molecular weight material is unex-
pected and requires further confirma-
tion.
Large doses of aqueous heparin, 1300
units or more per kilogram body weight,
administered endotracheally as an aero-
sol will produce a moderate anticoagulant
effect in man for up to 14 days.22 This
observation not only indicates a possible
new route for administration of heparin
but also points to a potential cellular
pooi for heparin storage that may exist
in reticuloendothelial cells from which it
is slowly released into plasma.
Individual variability in absorption of
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heparin after subcutaneous injection is
well recognized. Heparin may bind to tis-
sue proteins or be inactivated by tissue
enzymes, but the mechanism for varia-
tion in anticoagulant response has not yet
been clarified. Lower blood levels of hep-
arm have been detected after injection of
calcium as opposed to the sodium salt.m
Since no differences are seen after intra-
venous injection of these two heparin
salts, this difference may be related to a
lesser degree of absorption of the calcium
salt. This observation could explain a re-
port of a lower frequency of hemorrhagic
complications after subcutaneous admin-
istration of the calcium product.24 Others
have not confirmed this difference.25
After intravenous injection of heparin
in man, the apparent volume of distribu-
tion corresponds to the plasma volume.
Anticoagulant half-life, as measured by
clotting tests, is approximately 90 min-
utes and in the same subject does not
vary significantly with size of dose.2#{176}The
disappearance of heparin is that of a
first-order process. As noted above, there
may be extravascular uptake by reticulo-
endothelial cells.27 In addition, heparin
localizes on arterial and venous endothe-
hum in concentrations as great as 7500
times its concentration in blood.28”9
There are no new important discoveries
concerning the metabolism of heparin.
Although it has long been recognized that
only a small fraction of administered
heparin is excreted unchanged in the
urine, the pathways for degradation of
heparin within, the body have not yet
been fully delineated. Progressive desul-
fation appears to be one important ele-
ment in loss of anticoagulant activity.
Mechanism of Anticoagulant Effect
Some major recent advances have been
made in our knowledge of the anticoagu-
lant, and presumably antithrombotic, ac-
tion of heparin. Although the effect of
heparin upon platelet function has still
not been clarified, its function in modi-
fying clotting factor activity is much
better understood.
Prothrombin is converted to thrombin
by the combined action of factor V and
activated factor X in the presence of lipid
and calcium ions. In plasma there is an
alpha-2 globulin (antithrombin III; hep-
arm cofactor) which slowly complexes
stoichiometrically with thrombin through
combination of an arginine group on the
inhibitor with a serine center of throm-
bin. Heparin binds to antithrombin and
markedly accelerates the interaction of
thrombin and antithrombin.’#{176} This highly
specific effect of heparin upon antithrom-
bin appears to be catalytic rather than
stoichiometric.”
The heparin-antithrombin complex also
initiates the rapid inhibition of other
clotting factors which are serine pro-
teases: factors XII,3’ XI,33 and TX.35
Kallikrein, a proteolytic enzyme involved
in activation of factor XII, is also in-
hibited by this mechanism3#{176} as is plasmin,
the senile protease responsible for dis-
solution of intravascular thrombi.37 Al-
though a slow partial inactivation of fac-
tor VII by heparin-antithrombin com-
plex has also been reported,38 the kinetics
of this reaction differ from that observed
with the other clotting factors. The pres-
ence of adequate amounts of antithrom-
bin III is essential for heparin action
since patients with familial antithrombin
III deficiency have been shown to have a
deficient pattern of inactivation of throm-
bin by heparin.39
Observations concerning an effect of
heparin upon platelet function have been
contradictory. Heparin has been reported
to induce an increase, decrease, or no
change in platelet number, adhesiveness,
aggregation, and release reaction. Many
of these variable results may be due to
the unphysiologic conditions under which
the studies are carried out.4#{176}In a recent
in vivo study in rats, heparin was shown
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to decrease adhesion of platelets to vas-
cular endotheiium.4’ The tissue of origin42
and commercial source43 of heparin may
also influence results.
Toxicity and Hemorrhagic Complications
Extremely rare hypersensitivity reac-
tions and delayed transient alopecia have
long been recognized and do not appear
to have changed in frequency. For the
past 14 years reports have appeared of
rare instances of osteoporosis and com-
pression fractures after administration of
more than 10,000 units heparin per day
for three months or longer. A possible
mechanism for this side effect is the re-
cent demonstration that heparin com-
plexes with collagenase and that the com-
plex then binds to collagen, producing a
local increase in enzyme activity.44 In
addition, heparin has been shown to in-
crease the amount of procollagenase re-
leased from bone cultured in vitro.45
A great deal of interest has been ex-
pressed in heparin-associated thrombo-
cytopenia. Although a significant de-
crease in platelet count has been thought
to be infrequent, one recent study docu-
ments a marked decrease in platelets in
16 of 52 patients receiving five or more
days of continuous heparin infusion.’8
Since the pattern of platelet decrease
seems to vary in different subjects, more
than a single mechanism may be involved.
In some instances the decrease in platelet
number occurs within several minutes
after heparin administration while in
others the reduction in platelet count oc-
curs over a period of two to ten days.
Although some episodes appear to be im-
munologically mediated,46 others may be
related to initiation of platelet aggrega-
tion and sequestration.47 Until more data
are available concerning the frequency of
a clinically significant depression of plate-
let, periodic monitoring of platelet num-
ber appears indicated. Measurement of
platelets would be particularly impor-
tant after appearance of a hemorrhagic
complication since the approach to man-
agement would differ if thrombocytopenia
complicates heparin-associated bleeding.
Several epidemiologic factors are
known to alter the risk of bleeding dur-
ing heparin therapy. Elderly patients
(age 60 and over) develop hemorrhagic
complications with a frequency 50 to 100
per cent greater than that of younger
subjects.48’49 Of greatest importance is
the presence of any disease or condition
or drug that independently alters one or
another phase of the hemostatic mecha-
nism.5#{176}One frequently neglected initiat-
ing factor is the presence of drug-induced
abnormalities in patients concomitantly
receiving aspirin or other drugs affecting
platelet function. Administration of. etha-
crynic acid has been thought to potenti-
ate the risk of bleeding during heparin
therapy, but gastrointestinal bleeding is
also more frequent in patients receiving
ethacrynic acid alone.5’
Management of Heparin Therapy
During the more than 50 years that
heparin has been in clinical use, the con-
ventional routes of administration have
included continuous infusion, intermit-
tent intravenous injection, and subcutane-
ous and intramuscular injection. A
greater frequency of local hematoma for-
mation has resulted in the abandonment
of intramuscular injections.
There has been a recent increase in
utilization of continuous infusion of hep-
parin, based upon the results of several
prospective trials comparing this method
with intermittent intravenous injection
in the management of patients with ve-
nous thromboembolism.52’53 Both trials
showed a very appreciable reduction in
hemorrhagic complications in the groups
receiving continuous infusion. In both in-
vestigations the patients receiving con-
tinuous infusions required a smaller daily
dose of heparin to achieve the same level
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of anticoagulation; this reduction in hep-
arm dosage may be responsible for the
fewer hemorrhagic complications.
Although no difference in the fre-
quency of thrombotic complications was
noted in either study, the numbers of pa-
tients with recurrent thromboembolism
were too small to make differentiation
possible. An animal study based upon
measurement of accretion of isotope-la-
beled fibrinogen on jugular vein thrombi
in rabbits has demonstrated a significantly
lesser degree of thrombus propagation
when continuous infusion was compared
with intermittent intravenous injection of
heparin.54 A more recent third clinical
trial55 has provided contradictory data,
showing no appreciable differences in
total daily dosage of heparin or in hemor-
rhagic complications when continuous in-
fusion and intermittent intravenous in-
jection of heparin was compared. Al-
though this dilemma has not been fully
resolved, continuous infusion therapy may
prove to be preferable if appropriate
monitoring of coagulation profile indi-
cates that lesser amounts of heparin are
required and if suitable facilities and per-
sonnel are available to assure that the in-
fusion is carried out in a proper manner.
The feasibility of continuous infusion
therapy has been augmented by the avail-
ability of pumps for the regulation of
constant infusion. A bolus injection of
2500 to 5000 units dilute aqueous hep-
arm is given, and the infusion of heparin
in 5 per cent dextrose is started at a rate
of 1000 units per hour. Monitoring of an-
ticoagulant effect is begun at 3 hours
(approximately two anticoagulant half-
lives) and repeated frequently until dos-
age is adjusted to reach the desired end-
point for anticoagulant effect.
In the absence of a constant infusion
pump, several less desirable approaches
are available. A pediatric burette may
be utilized, to which is added a specified
volume of heparin solution at 1- to 2-
hour intervals. The amount of heparin
calculated for administration over a 4-
hour period may be added to several
hundred milliters of 5 per cent dextrose
in water and given by the usual intra-
venous drip infusion. If the rate of ad-
ministration is improperly regulated, the
patient receives no more heparin than
would be administered by intermittent
“pulse” therapy.
An alternative, and probably the most
frequently used, method is the injection
of approximately 5000 units heparin
(1000 units/mi) intravenously every 4
hours. Although pharmacokinetic data
may indicate that more frequent injec-
tion of smaller doses would be prefer-
able,26 such a regimen is less practicable
from the nursing standpoint. Frequent
‘‘pulse” injection is greatly facilitated
by a heparin “lock” (a small butterfly-
type needle with a rubber diaphragm
connected to a plastic catheter) which is
left within a superficial arm vein; suffi-
cient heparin usually remains within the
catheter to maintain patency for a con-
siderable period. Recent data seem to
indicate that monitoring anticoagulant ef-
fect in patients receiving intermittent
“pulse” therapy does not reduce the fre-
quency of bleeding, but monitoring at
approximately 1 hour before the next in-
jection may permit detection of an in-
adequate anticoagulant response and thus
assure adjustment of dosage.
Standard therapeutic doses of heparin
have also been given by subcutaneous in-
jection, usually at 12-hour intervals.
Aqueous concentrated heparin (20,000 to
40,000 units/mi) should be used since the
smaller volume of solution is associated
with a lower prevalence of local hema-
toma formation. To my knowledge a pro-
spective trial comparing subcutaneous
aqueous heparin with one of the other
methods of administration in the treat-
ment of established venous thrombosis has
not been conducted to determine relative
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efficacy and safety. It is more frequently
used for continued treatment of ambula-
tory nonhospitalized patients whose
thrombotic processes appear to be refrac-
tory to oral anticoagulant therapy. It
is also of considerable value in long-term
therapy in pregnant patients, particu-
larly during the first trimester, when the
teratogenic hazards of oral anticoagulants
should be avoided. Frequent laboratory
monitoring is essential because of con-
siderable interindividual variability in
rates of absorption and possible delayed
shifts of heparin from cellular pools to
the intravascular compartment.
Several investigators56’57 have recom-
mended that patients with pulmonary
embolism receive one or more large in-
itial doses of heparin (15,000 to 20,000
units) to attempt to reduce accretion of
platelets on emboli and release of vaso-
active amines58 or to neutralize the effect
of release of the platelet antiheparin fac-
tor,59 but no data are available to show
that this approach has an effect upon
morbidity or mortality. However, patients
with pulmonary embolism or other ex-
tensive thrombotic processes have been
shown to have a lesser anticoagulant re-
sponse to a fixed dose of heparin when
monitored by the activated partial throm-
boplastin time (APTT) .0 During the in-
itial hours or days of therapy these pa-
tients may require larger doses of heparin
to achieve the same endpoint in anticO-
agulant response.
Whether routine calculation of daily
dosage of heparin should be based upon
body weight is debatable. Although, in
general, small thin subjects appear to re-
quire lesser amounts of heparin, many
other variables that affect heparin re-
sponse make such estimates very uncer-
tain.
As noted above, the safety and possibly
the efficacy of heparin therapy admin-
istered by continuous infusion or sequen-
tial subcutaneous injection appears to be
favorably influenced by laboratory moni-
toring. The procedures most commonly
used for control are the APTT or the
thrombin clotting time (TOT). Lee-
White clotting times have for the most
part been abandoned as too cumbersome,
time consuming, and inaccurate. Re-
gardless of the method used, individual
calibration and adjustment of the proce-
dure may be necessary to assure a rela-
tively linear response to varying levels
of heparin. The APTT has a low sensi-
tivity in detecting heparin when many
commercially prepared reagents are
used.6’ Another concern is that a large
number of hospitalized patients not re-
ceiving heparin have prolongations of
the APTT.#{176}’ Some investigators have
found the APTT to be less satisfactory
in controlling heparin therapy than the
TCT,63 factor Xa assay,#{176}4’#{176}5polybrene
titration,66’67 or activated recalcification
time.68’69 Since these and a number of
other tests have been advocated for hepa-
rin monitoring, it is obvious that the ideal
procedure has not yet been devised.
Since inter- and intraindividual vari-
ability in response to heparin is well rec-
ognized,26’70.#{176}#{176}monitoring of all patients
receiving therapeutic doses of heparin
has the potential to lessen morbidity. Pro-
longation by heparin of the APTT to
1#{189}times control will inhibit thrombosis
in rabbits.7’ A similar level of anticoagu-
lation appears to be effective in man,
while a lesser effect (APTT of less than
50 seconds for three consecutive days)
was associated with a risk of recurrent
thrombosis of 25 per cent.7’ A prolonga-
tion of the APTT to 11/2 to 3 times nor-
mal or the TOT to 2 to 3 times normal
is roughly comparable to a two- to three-
fold lengthening of the Lee-White clot-
ting time.
The optimum duration of heparin
therapy for venous thromboembolism has
not been determined, but later recurrence
of thrombosis can be lessened by a corn-
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bination of initial heparin and subse-
quent prolonged oral anticoagulant treat-
ment.73 Most clinicians administer hepa-
nfl for one to three weeks, the duration
based upon the extensiveness of the
thrombotic process. Since five to seven
days of administration of oral anticoagu-
lant is required to achieve maximum de-
pression of vitamin K-dependent clotting
factors, heparin and oral anticoagulant
treatment is overlapped for this period
before heparin is stopped.
There are no new developments in
the approach to reversal of the anti-
coagulant effect of heparin. Protamine
sulfate, administered intravenously in a
dose of 1.0 to 1.25 mg per 100 units of
estimated circulating heparin, remains
the agent of choice. The relatively short
anticoagulant half-life of intravenously
administered heparin should be taken
into account in estimating dose of pro-
tamine since an excess of circulating pro-
tamine also results in a transient anti-
coagulant effect. Sequential laboratory
monitoring of coagulation should be per-
formed because a secondary rebound may
occur from dissociation of the heparin-
protamine complex or from further re-
lease of heparin from cellular pools.
Bleeding after subcutaneous administra-
tion of heparin requires administration
of a bolus of protamine followed by an
infusion of this agent over the expected
period of continued absorption of the
heparin from the subcutaneous depot.
Other Effects of Heparin
The mechanisms involved in the lipoly-
tic effect of heparin74’75 and the numerous
other “side effects” of heparin7#{176} have
been reviewed elsewhere. A recently dis-
covered ancillary effect of heparin which
has reached the clinical horizon is the in-
fusion of solutions of heparin via a tube
in the common bile duct to attempt to
achieve the dissolution of retained gall-
stones. This therapy has been based upon
the concept that the high electronegative
charge on the heparin molecule might im-
prove colloidal suspension stability of bile
by altering particle surface charge and
thus cause gallstones to fragment.77 Re-
sults with this approach have been van-
able.788#{176} The successful results may be
secondary to the flushing effect of the
continuous infusion into the common bile
duct since infusion of saline alone has
also been effective.8’
Other Clinical Applications
In the past ten years the gradual evo-
lution of the use of heparin for the pro-
phylaxis of venous thromboembolism has
produced a major increase in total
amount of heparin administered. The po-
tential value of the utilization of smaller
amounts of heparin injected subcutane-
ously for prevention of postoperative
venous thromboembolism was first re-
ported by Sharnoff82; its widespread use
in the past five years has followed con-
firmation of the effectiveness of this rou-
tine in prospective controlled trials in
which the frequency of thrombosis has
been documented with P’5-fibrinogen
scanning.
The rationale for this “low dose” regi-
men is based upon the concept that lesser
amounts of heparin are needed to prevent
the initiation of a thrombus than to pre-
vent its propagation. Small amounts of
heparin markedly increase the rate of
inhibition of activated factor X(Xa) by
antithrombin III. One microgram of anti-
thrombin-heparin complex, by inhibiting
the activity of 32 units Xa, prevents the
potential activation of 1600 units throm-
bin; the neutralization of this amount of
thrombin would require 1000 micrograms
antithrombin.83 It is possible that this
suppression of thrombus development
may also be mediated by more rapid in-
hibition of other activated serine pro-
teases (XIIa, XIa, IXa), but this has not
yet been proved.
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Although dozens of controlled trials
utilizing labeled fibrinogen or venogra-
phy for diagnosis have been published in
the past few years, the scope of effective-
ness and limitations of low-dose heparin
therapy have not yet been fully defined.
The majority of these studies have been
conducted in surgical patients. In 17 of
19 studies of patients undergoing thor-
acic, abdominal, or urologic operations
that have been recently summarized,84 a
significant reduction in postoperative
thrombosis was observed. The mean de-
crease in frequency of venous thrombosis
was about threefold. However, this ap-
proach is of no or very limited value in
orthopedic patients, particularly those
with femoral fractures and reconstructive
procedures about the hip and knee, and
urologic patients having an open prosta-
tectomy; its efficacy in patients undergo-
ing total removal of the rectum for can-
cer is also uncertain. More severe direct
venous trauma and possible increased ac-
tivation of the clotting mechanism
through the release of thromboplastic
agents from tissues have been proposed
as possible mechanisms to explain the
failure of low-dose heparin under these
circumstances.
This prophylactic regimen is effective
in reducing the frequency of leg vein
thrombosis in patients with acute myo-
cardial infarction and congestive heart
failure.85’86 Although it should also be of
value in other medical and neurologic
patients who are at increased risk of
venous thrombosis because of paralysis,
confinement to bed, etc., appropriate con-
trolled studies have not yet been con-
ducted.
Since the prevalence of leg vein
thrombi detected by labeled fibrinogen is
10 to 50 per cent in high-risk medical
and surgical patients, the clinical im-
portance of reducing the frequency of
these thrombi, most of which are confined
to the calf veins, has been questioned.
Several recent investigations have now
confirmed that in suitable subjects, as
mentioned above, low-dose heparin also
reduces the frequency of iiofemoral ve-
nous thrombi87 and of nonfatal and fatal
pulmonary embolism.88’89
Most of the controlled trials have used
one of two standard dosage regimens: the
injection of 5000 units aqueous concentra-
ted heparin at 8-hour or 12-hour intervals.
Hepanin should be in concentrated form
(20,000 units/ml), and volume should be
accurately measured to minimize the risk
of hemorrhage. In surgical patients the
first dose is usually administered 2 hours
before operation and continued postop-
eratively until the patient is fully am-
bulatory. However, in one recent study
of surgical patients admitted to the hos-
pital more than four days before opera-
tion, 62 per cent of all leg vein thrombi
which were detected appeared before the
operation.9#{176} This observation points to a
need for earlier hepanin prophylaxis in
patients requiring extensive preoperative
investigations. Bleeding has not been a
problem in the majority of trials utilizing
a twice-daily dosage routine, while there
has been a small increase in operative
blood loss and postoperative bleeding in
patients receiving hepanin every 8 hours.
Although the three-times-daily regimen
was instituted in an attempt to achieve
a greater antithrombotic effect in high-
risk patient groups, these two routines
have not yet been compared for risk-
benefit ratio in prospective studies. At
present the use of low-dose heparin is
contraindicated in patients having spinal
or epidural anesthesia and operations
upon the brain, spinal cord, or eye.
The limited effectiveness of low-dose
heparin in certain orthopedic patients has
stimulated interest in the utilization of
combinations of heparin and dextran or
heparin and aspirin. No appropriately
controlled studies have been reported;
the significant increase in hemorrhagic
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risk when two agents affecting different
phases of hemostasis are given in com-
bination should be appreciated.5#{176} A ran-
domized trial of patients undergoing total
hip replacement has compared the effect
of low-dose heparin alone with low-dose
heparin plus dihydroergotamine and re-
ported a significant reduction in leg vein
thrombosis in the latter group.84 Dihy-
droergotamine is thought to have an ad-
ditive effect by increasing venous flow
and possibly by stimulating the release
of plasminogen activator from the vein
wall.
Although sufficient data are available
to suggest that the broad use of low-dose
hepanin prophylaxis will reduce the fre-
quency of fatal pulmonary embolism, the
issues of patient selection and cost-bene-
fit ratio have not yet been resolved. Most
trials in surgical subjects have encom-
passed all patients age 40 years and over
undergoing major operations. If these
criteria are utilized, the population at
risk is extremely large; the demands on
hepanin production and the increase in
nursing load would be appreciable. Fur-
ther restriction of criteria for patient se-
lection may be necessary in order to make
this prophylactic approach cost effec-
tive.9’ This will be particularly important
if the well-recognized interindividual
variability in response to a fixed dose of
hepanin necessitates laboratory monitor-
ing of low-dose hepanin routines in order
to lessen the increased frequency of
bleeding.
Another clinically applicable innova-
tion is the development of methods for
bonding of hepanin to biomaterials. The
transient placement of catheters within
arteries and veins and the more perma-
nent placement of prosthetic materials in
the cardiovascular system has led to a
search for materials less susceptible to
thrombus formation. Over the past 15
years techniques have been developed for
the bonding of heparin to polystyrene,
polyethylene, poly (vinyl chloride), colla-
gen, silicon rubber, nylon, etc.92 Heparin
has also been bonded to a polyester fiber
that can be subsequently knitted or woven
into tubular vascular prostheses. A cur-
rent popular method for bonding in-
volves the application to the material of
a complex of tridodecylmethylammonium
chloride and hepanin.92 Gamma irradia-
tion has also been shown to bond hepanin
to cellular membranes.#{176}3
Many heparin-bonded foreign surfaces
have not inhibited platelet adhesion and
subsequent platelet embolism,94 but a
polyurethane-heparin complex95 and hep-
aria-bonded polyethylene96 appear to
have some effect upon inhibition of plate-
let deposition. The mechanism of resis-
tance to thrombus formation by heparin-
bonded surfaces is still being debated;
some studies show a delay in coagulation
when blood is in contact with such a sur-
face,97 while others attribute the effect to
slow leaching of heparin from the ma-
terial. There is some preferential adsorp-
tion of antithrombin III, factors IX and
XI, and thrombin to the bonded sur-
face.98
Large heparin-bonded catheters have
been used in man for temporary bypass
of the descending thoracic aorta during
insertion of a prosthetic vascular graft.
A very practical future application would
be the development of smaller heparin-
bonded vascular catheters.’#{176}#{176}”#{176}’Since
these catheters, which are currently left
in blood vessels for periods that vary
from hours to days or weeks, rapidly de-
velop a sleeve of fibnin which may occlude
the vessel or catheter lumen or embolize,
any development that might lessen the
frequency of these complications would
be of considerable practical value.
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